ANDREW A. MCLEOD, M.B., M.R.C.P.; DAVID G. SHAND, PH.D.
This content is PDF only. Please click on the PDF icon to access.
Atenolol, a selective beta1-adrenoceptor antagonist, has recently received FDA approval for release in the United States for the treatment of hypertension. Propranolol, the prototype betaadrenoceptor blocker for clinical use, has been used in humans for a decade and a half. More recently, metoprolol and nadolol have received approval for clinical use in the United States. Atenolol was released in Europe in 1976 and has been studied widely and carefully. To most practicing physicians, a drug with the same therapeutic characteristics as others already available is not uncritically welcomed. Prescribes will seek evidence that a new agent has pharmacodynamic or pharmacokinetic
MCLEOD AA, SHAND DG. Antenolol: A Long-Acting Beta1-Adrenoceptor Antagonist. Ann Intern Med. 1982;96:244–245. doi: 10.7326/0003-4819-96-2-244
Download citation file:
Published: Ann Intern Med. 1982;96(2):244-245.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use